PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION June 13, 2005 (Use several sheets if necessary)	4033.3000 US	U.S. NATIONAL PHASE OF INTERNATIONAL APPLICATION NO. PCT/GB2003/003236	
	FILING DATE	ASSIGNED UNITED STATES APPLICATION NO.: 10/521,522	
	PIRST NAMED APPLICANT Andrew Powell	CONFIRMATION NO.	(639

Γ		===		U.S. PA	TENT DOCU	MENTS			
		REF.	DOCUMENT NUMBER		1	IM-DD-YYYY SSUE DATE / LICATION DATE	NAME OF PATEN CITED	TEE OR APP	
1	W	AA	US-5,430,133		July 4,1995	}	Piani, et al.		
115 5 405 040		April 11, 1	995	Ungarelli, et al.					
Γ	110 5 542 402		August 6, 1	996	Petitou, et al.				
r		. AD US-5,958,899		September	28, 1999	Zoppetti, et al.			
		AE	US-4,717,719		January 5,	1988	Sportoletti, et al.		
Γ	,	AF	F US-6,127,347		October 3,	2000	Holme, et al.		
Г		AG 5,795,860		08-18-1998	3	Witt et al.			
Ι,		AH	US 2001/0051349 A1		12-13-2001		Dukler et al.		
FOREIGN PATENT DOCUMENTS									
			DOCUMENT NUMBER		DD-YYYY ATION DATE	NAME OF PATENTEE OF		TRANS	LATION NO
	tw	AL	EP 0380719	1990-	AUG-08	AJORCA SA (AR) Domanico Ricardo Hu	igo, et al.		
┞	۲,	АМ	EP 0 557 887 B1	12-1	7-1997	Lino Liverani et al.	-		
Γ	1	AN	WO 01/40796 A3	06-0	7-2001	Thermo Hybaid GM	BH et al.		

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
Mlu	AR	Kariya, Yutaka, et al., "Preparation of Completely 6-O-Desulfated Heparin and Its Ability to Enhance Activity of Basic Fibroblast Growth Factor," J. Biol. Chem., 275(34): 25949-25958 (2000).
·	AS	Yates, Edwin A., et al., "Evidence for a Heparin Derivative Containing an N-Sulfated Aziridine Ring that Retains High Anti-Factor Xa Activity," Carbohydr. Res., 298:335-340 (1997).
	AT	M. Jaseja, et al., "Novel Regio- and Stereoselective Modifications of Heparin in Alkaline Solution. Nuclear Magnetic Resonance Spectroscopic Evidence," Can. J. Chem., 67:1449-1456 (1989).
,	ΑU	Guimond, S.E. and Turnball, J.E., "Fibroblast Growth Factor Receptor Signalling is Dictated by Specific Heparan Sulphate Saccharides," Curr Biol., 9:1343-1346 (1999).
	AV	Irie, A., et al., "Specific Heparan Sulfate Structures Involved in Retinal Axon Targeting," Development, 129: 61-70 (2002).
4	AW	Kreuger, J., et al., "Sequence Analysis of Heparan Sulfate Epitopes with Graded Affinities for Fibroblast Growth Factors 1 and 2," J. Biol Chem., 276(33): 30744-30752 (2001).

EXAMINER T. D. M	DATE CONSIDERED VI /26/07
	<u> </u>

INFORMATION DISCLOSURE CITATION IN AN APPLICATION June 13, 2005 (Use several sheets if necessary)	4033.3000 US	U.S. NATIONAL PEASE OF INTERNATIONAL APPLICATION NO. PCT/GB2003/003236	
	PILING DATE	ASSIGNED UNITED STATES APPLICATION NO.: 10/521,522	
	PIRST NAMED APPLICANT Andrew Powell	CONFIRMATION NO.	GROUP 1639

<u>IL</u>	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
1	d	AX	Nadkarni, V.D. and Linhardt, R.J., "Directional Immobilization of Heparin onto the Nonporous Surface of Polystyrene Microplates," <i>Biotechniques</i> , 23:382-385 (1997).	
	1	AY	Nadkarni, V.D., et al., "Directional Immobilization of Heparin onto Beaded Supports," Anal Biochem., 222: 59-67 (1994).	
4		AZ	Yates, Edwin A., et al., "H and C NMR Spectral Assignments of the Major Sequences of Twelve Systemically Modified Heparin Derivatives," Carbohydrate Research, 294: 15-27 (1996).	
,		AR2	Dove, Alan, "The Bittersweet Promise of Glycobiology," Nature Biotechnology, 19: 913-917 (2001).	
~	V	AS2	Database Biosis, Biosciences Information Service, Philadelphia, PA, US. Wu, Zhengliang L., et al., "A New Strategy for Defining Critical Functional Groups on Heparan Sulfate," FASEB J., 16(6), XP002268531 abstract (2002).	

EXAMINER T. D.

DATE CONSIDERED